Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

L Topalian, Suzanne; Stephen Hodi, F; R Brahmer, Julie; N Gettinger, Scott; C Smith, David; F McDermott, David; D Powderly, John; D Carvajal, Richard; A Sosman, Jeffrey; B Atkins, Michael; D Leming, Philip; R Spigel, David; J Antonia, Scott; Horn, Leora; G Drake, Charles; M Pardoll, Drew; Chen, Lieping; H Sharfman, William; A Anders, Robert; M Taube, Janis; L McMiller, Tracee; Xu, Haiying; J Korman, Alan; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; D Kollia, Georgia; Gupta, Ashok; M Wigginton, Jon; Sznol, Mario

doi:10.1056/NEJMoa1200690

Public

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Shared by NobleBlocks on Jun 28, 2012 • 12:00 AM UTC

Authors:

Suzanne L Topalian

F Stephen Hodi

Julie R Brahmer

Abstract

BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma, non-small-cell...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!